Healthcare Supplies firm Nureca announced Q1FY23 Result : GMV of Q1’FY23 stood at Rs. 338 mn as compared to Rs. 1627 Mn in Q1’FY22, decrease of 79% Operating Revenue was Rs. 255 mn in Q1’FY23 as compared to Rs. 1,195 in Q1’FY22, decrease of 79% Overall, demand has seen a dip in Q1’FY23 as compared to the same quarter last year, which had seen a huge surge in demand due to Covid-19 Our Gross margins in Q1’FY23 were impacted due to lower demand, inflation in input cost, currency fluctuation as well as inflationary pressure in other non-core costs such as packaging, transport, etc. Our employee cost has increased as compared to the same quarter last year due to aggressive talent acquisition across the business functions and verticals majorly for app development and expansion of Offline distribution network. Other expenses are lower in Q1’FY23 by 52%, in line with the top line. Overall, EBITDA was Rs. (46) mn in Q1’FY23, lower by 109% and PAT stood at Rs. (41) mn, lower by 111% Result PDF
Healthcare Supplies firm Nureca declares Q4FY22 result: GMV for the FY22 at Rs. 3,403mn as compared to Rs. 2,994mn in FY21, an increase of 14% Operating Revenue was Rs. 2,555mn in FY22 as compared to Rs. 2,135mn in FY21, an increase of 20% Adjusted EBITDA was Rs. 664mn as compared to Rs. 644mn in FY21, an increase of 3% PAT stood at Rs. 450mn as compared to Rs. 464mn in FY21, degrowth of 3% EPS for the FY22 was Rs. 45.0 compared to Rs. 62.0 in FY21. The decline was mainly due to a higher base which is a result of fundraising during the current year. In Q4FY22, We had several one-off costs in terms of professional and legal consultancy fees, setting up of various frameworks and other smaller one-time expenses During the quarter, Aryan Goyal, Founder & CEO of Nureca, was awarded “Top 40 under 40” of the Indian healthcare ecosystem by BW Businessworld Our Employee expenses more than doubled this year as we continue to acquire more talent to expand various business verticals such as Offline entry, Health-tech Platform, entry into Nutraceuticals, baby products, etc. During the quarter we added number new features to our AI driver platform – Dr. Trust 360. This is inline with our strategy of creating a smart home and healthcare ecosystem for our customers. We forayed into the offline market recently and built a strong presence in 22 states and UTs with 120 distributors covering 9000 retail outlets across India. Result PDF
Highlights: GMV for the H1F22 at Rs. 2,285mn as compared to Rs. 1,826mn in H1FY21, an increase of 30% Operating Revenue was Rs. 1,664mn in H1FY22 as compared to Rs. 1,221mn in H1FY21, an increase of 36% Our core products i.e. Bp monitor and Glucometer, both continue to outperform the market with revenue from both products more than 60% in H1FY22 compared to same period last year EBITDA was Rs. 574mn as compared to Rs. 500mn in H1FY21, an increase of 15% PAT stood at Rs. 416mn as compared to Rs. 362mn in H1FY21, a growth of 15% Strong balance sheet with Cash and Cash equivalents of Rs. 127 cr. as of September 20721 Result PDF